Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
COVID-19
Delta
Omicron
SARS-CoV-2
antibody neutralization
antigenic variants
convalescent plasma
vaccination
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
19
04
2022
received:
17
02
2022
accepted:
19
04
2022
pubmed:
20
5
2022
medline:
14
7
2022
entrez:
19
5
2022
Statut:
ppublish
Résumé
The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID-19 may derive from neutralizing antibodies (nAbs) to SARS-CoV-2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS-CoV-2, including Delta and Omicron, in CP donors previously infected with SARS-CoV-2 before and after immunization. Samples were assayed from previously SARS-CoV-2 infected donors before (n = 17) and after one (n = 43) or two (n = 71) doses of Astra-Zeneca or Pfizer vaccinations. Ab titers against Wuhan/wild type (WT), Alpha, Beta, and Delta SARS-CoV-2 strains were determined by live virus microneutralization assay while titers to Omicron used a focus reduction neutralization test. Anti-spike antibody was assayed by Elecsys anti-SARS-CoV-2 quantitative spike assay (Roche). Unvaccinated donors showed a geometric mean titer (GMT) of 148 against WT, 80 against Alpha but mostly failed to neutralize Beta, Delta, and Omicron strains. Contrastingly, high GMTs were observed in vaccinated donors against all SARS-CoV-2 strains after one vaccine dose (WT:703; Alpha:692; Beta:187; Delta:215; Omicron:434). By ROC analysis, reactivity in the Roche quantitative Elecsys spike assay of 20,000 U/mL was highly predictive of donations with nAb titers of ≥1:640 against Delta (90% sensitivity; 97% specificity) and ≥1:320 against Omicron (89% sensitivity; 81% specificity). Vaccination of previously infected CP donors induced high levels of broadly neutralizing antibodies against circulating antigenic variants of SARS-CoV-2. High titer donations could be reliably identified by automated quantitative anti-spike antibody assay, enabling large-scale preselection of high-titer convalescent plasma.
Sections du résumé
BACKGROUND
The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID-19 may derive from neutralizing antibodies (nAbs) to SARS-CoV-2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS-CoV-2, including Delta and Omicron, in CP donors previously infected with SARS-CoV-2 before and after immunization.
METHODS AND MATERIALS
Samples were assayed from previously SARS-CoV-2 infected donors before (n = 17) and after one (n = 43) or two (n = 71) doses of Astra-Zeneca or Pfizer vaccinations. Ab titers against Wuhan/wild type (WT), Alpha, Beta, and Delta SARS-CoV-2 strains were determined by live virus microneutralization assay while titers to Omicron used a focus reduction neutralization test. Anti-spike antibody was assayed by Elecsys anti-SARS-CoV-2 quantitative spike assay (Roche).
RESULTS
Unvaccinated donors showed a geometric mean titer (GMT) of 148 against WT, 80 against Alpha but mostly failed to neutralize Beta, Delta, and Omicron strains. Contrastingly, high GMTs were observed in vaccinated donors against all SARS-CoV-2 strains after one vaccine dose (WT:703; Alpha:692; Beta:187; Delta:215; Omicron:434). By ROC analysis, reactivity in the Roche quantitative Elecsys spike assay of 20,000 U/mL was highly predictive of donations with nAb titers of ≥1:640 against Delta (90% sensitivity; 97% specificity) and ≥1:320 against Omicron (89% sensitivity; 81% specificity).
DISCUSSION
Vaccination of previously infected CP donors induced high levels of broadly neutralizing antibodies against circulating antigenic variants of SARS-CoV-2. High titer donations could be reliably identified by automated quantitative anti-spike antibody assay, enabling large-scale preselection of high-titer convalescent plasma.
Identifiants
pubmed: 35588314
doi: 10.1111/trf.16934
pmc: PMC9348319
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1347-1354Subventions
Organisme : Department of Health
ID : RECPLAS
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.
Références
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Science. 2021 Mar 25;:
pubmed: 33766944
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
J Infect Dis. 2022 Mar 15;225(6):971-976
pubmed: 34751775
JAMA. 2021 Nov 02;326(17):1690-1702
pubmed: 34606578
Euro Surveill. 2021 Jul;26(27):
pubmed: 34240697
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Am J Pathol. 2021 Jan;191(1):90-107
pubmed: 33157066
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700670
Transfusion. 2022 Jul;62(7):1347-1354
pubmed: 35588314
Science. 2022 Jan 14;375(6577):183-192
pubmed: 34855510
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470